Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B

Gastroenterology

Volumn 139, Issue 2, 2010, Pages 491-498

  Reijnders, Jurriën G P ^a   Perquin, Moniek J ^a   Zhang, Ningping ^a,b   Hansen, Bettina E ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b FUDAN UNIVERSITY   (China)

Author keywords

Antiviral Therapy; Discontinuation; Durability; Sustained Response

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; NUCLEOSIDE; NUCLEOTIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASIAN; CAUCASIAN; CLINICAL EVALUATION; COHORT ANALYSIS; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; REMISSION; SEROCONVERSION; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ANTIVIRAL RESISTANCE; BIOASSAY; BLOOD; DRUG ADMINISTRATION; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; ENDPOINT DETERMINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77955485392     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.03.059     Document Type: Article

References (32)

1. M.F. Sorrell, E.A. Belongia, J. Costa, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B Ann Intern Med 150 2009 104 110
2. F. Bortolotti, M. Guido, S. Bartolacci, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study Hepatology 43 2006 556 562
3. G. Fattovich, M. Rugge, L. Brollo, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B Hepatology 6 1986 167 172
4. J.H. Hoofnagle, G.M. Dusheiko, L.B. Seeff, et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis Ann Intern Med 94 1981 744 748
5. Y.S. Hsu, R.N. Chien, C.T. Yeh, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527
6. A.S. Lok, C.L. Lai, P.C. Wu, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection Gastroenterology 92 1987 1839 1843
7. B.J. McMahon, P. Holck, L. Bulkow, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus Ann Intern Med 135 2001 759 768
8. J.L. Dienstag Benefits and risks of nucleoside analog therapy for hepatitis B Hepatology 49 2009 S112 S121
9. European Association for the Study of the L EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
10. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
11. J.L. Dienstag, J. Cianciara, S. Karayalcin, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B Hepatology 37 2003 748 755
12. B.C. Song, D.J. Suh, H.C. Lee, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
13. T. Poynard, J. Hou, A. Chutaputti, et al. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine and lamivudine J Hepatol 48 2008 S263
14. E.H. Buster, H.J. Flink, Y. Cakaloglu, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 2008 459 467
15. J. Korenman, B. Baker, J. Waggoner, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy Ann Intern Med 114 1991 629 634
16. P. Marcellin, F. Bonino, G.K. Lau, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a Gastroenterology 136 2009 2169 2179
17. C.J. Chen, H.I. Yang, J. Su, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
18. U.H. Iloeje, H.I. Yang, J. Su, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 2006 678 686
19. S.D. Pas, E. Fries, R.A. De Man, et al. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays J Clin Microbiol 38 2000 2897 2901
20. S.D. Pas, and H.G. Niesters Detection of HBV DNA using real time analysis J Clin Virol 25 2002 93 94
21. G.J. van Doornum, J. Guldemeester, A.D. Osterhaus, et al. Diagnosing herpesvirus infections by real-time amplification and rapid culture J Clin Microbiol 41 2003 576 580
22. K.S. Byun, O.S. Kwon, J.H. Kim, et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy J Gastroenterol Hepatol 20 2005 1838 1842
23. R.N. Chien, C.T. Yeh, S.L. Tsai, et al. Determinants for sustained HBeAg response to lamivudine therapy Hepatology 38 2003 1267 1273
24. J.H. Kim, S.J. Lee, M.K. Joo, et al. Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation Dig Dis Sci 54 2009 1572 1577
25. C.M. Lee, G.Y. Ong, S.N. Lu, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation J Hepatol 37 2002 669 674
26. H.C. Lee, D.J. Suh, S.H. Ryu, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion Gut 52 2003 1779 1783
27. K.M. Lee, S.W. Cho, S.W. Kim, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion J Viral Hepat 9 2002 208 212
28. S.H. Ryu, Y.H. Chung, M.H. Choi, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study J Hepatol 39 2003 614 619
29. A.B. van Nunen, B.E. Hansen, D.J. Suh, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase Gut 52 2003 420 424
30. I.C. Wu, M.L. Shiffman, M.J. Tong, et al. Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants Clin Infect Dis 47 2008 1305 1311
31. S.K. Yoon, J.W. Jang, C.W. Kim, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion Intervirology 48 2005 341 349
32. C.T. Frenette, and R.G. Gish To "be" or not to "be": that is the question Am J Gastroenterol 104 2009 1948 1952